Citi analyst Liav Abraham removed Mylan from his US Focus List, telling investors in a research note that he remains “constructive” on Mylan the recent FDA approval of Fulphila and slight delay to the approval of generic Advair, and says he views the recent share price reaction following the delay announcement as “overdone.” He still expects to see potential approval in the latter part of 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.